Regeneron’s Eylea Could Lose 30% of its Patients to Roche’s Vabysmo Over the Next Year: Analyst Survey
Biohaven’s Nurtec ODT and AbbVie’s Qulipta Emerging as the Top Two Contenders in the Preventive Migraine Space, According to Spherix Global Insights
Growth of newer market entrants resulting in relatively flat projected share for Eli Lilly’s Emgality, Teva’s Ajovy, and Amgen’s Aimovig EXTON, Pa., June 10, 2022 /PRNewswire – According to the latest deep dive report included in Spherix’s Launch Dynamix™: Qulipta for Migraine Prevention (US) service, surveyed neurologists and migraine specialists report high satisfaction with AbbVie’s Qulipta […]
Vyvgart’s Novel Mechanism of Action and Efficacy Are Top Advantages of the Brand, According to Neurologists Surveyed by Spherix Global Insights
Data suggest potential competitive edge over Alexion’s Soliris on multiple treatment metrics EXTON, Pa., June 9, 2022 / PRNewswire/ — Three months into the launch of argenx’s Vyvgart for generalized myasthenia gravis (gMG) in patients who are anti-acetylcholine receptor antibody (ACh-R) positive, neurologists identified (unaided) the brand’s novel mechanism of action as the first neonatal […]
Nephrologists Await Advanced Pipeline Agents, Including Venglustat (Sanofi), Lucerastat (Idorsia), and PRX-102 (Protalix), to Address High Unmet Need in Fabry Disease, Spherix Reports
Diagnosis, treatment, management, the increasing role of genetic testing, and the future promise of gene therapy captured in new report EXTON, Pa., / June 8, 2022/PRNewswire – Fabry disease is an extremely rare genetic condition most prevalent in men and potentially underdiagnosed in women. Nephrologists rank it as one of the most difficult conditions to […]
Changes Afoot in US Age-Related Macular Degeneration Market as Prescribers Brace for the Launch of Biogen and Samsung Bioepis’ Byooviz, According to Spherix Global Insights
Physician-reported treatment patterns suggest that Byooviz could soon be competitive with Genentech’s Lucentis, but not likely to displace Regeneron’s Eylea EXTON, Pa., June 8, 2022 / PRNewswire/ — After several years of lackluster reception towards off-label biosimilar, Genentech’s Avastin (bevacizumab), ophthalmologists have finally seen the greenlight of a biosimilar that was studied and FDA approved […]
Spherix Global Insights Announces Fielding of New Research Geared Towards Fellows and Residents in Immunology, Neurology, Nephrology, and Ophthalmology
The project is designed to explore to what degree the next generation of specialists are prepared to enter clinical practice and what baseline opinions will they be bringing as they move from a training environment into real world patient management EXTON, Pa., June 7, 2022 /PRNewswire/ — Fellows will be the next generation of practitioners. […]
AbbVie’s Rinvoq Already Flexing Its Promotional and Efficacy Muscles to Impact the Ulcerative Colitis Market, According to Spherix Global Insights
Gastroenterologists report strong awareness, familiarity, and patient initiations for Rinvoq, relative to recent launches EXTON, Pa., June 7, 2022 /PRNewswire – According to the latest deep dive report published as part of Spherix’s Launch Dynamix™: Rinvoq in Ulcerative Colitis (US) service, AbbVie’s recently-approved JAK inhibitor is poised to shake up the ulcerative colitis (UC) market, especially […]
Spherix Global Insights Announces Entry into Asia-Pacific Research with Upcoming IgA Nephropathy Market and Pipeline Assessment in Japan
The first IgA Nephropathy (Japan) study, due to release later this summer, pairs with other studies in the EU5 and United States EXTON, Pa., June 2, 2022 /PRNewswire/ — Glomerulonephritis is a major contributor of end-stage renal disease across the globe, with IgA nephropathy (IgAN), also known as Berger’s disease, as the most common […]
Biogen, Samsung Bioepis Launch First US Biosimilar, a Copycat of Roche’s Lucentis, at 40% Discount
Despite the partners’ excitement, a recent survey by Piper Sandler and Spherix Global Insights found that in the presence of Regeneron’s market-leading anti-VEGF eye drug, Eylea, ophthalmologists are “largely ambivalent” with Byooviz and other VEGF copycats of Roche’s Avastin.
Diabetes-Related Mechanisms of Action Make Their Move as Several NAFLD/NASH Pipeline Therapies Inch Closer to the First-Ever FDA Approval
Ten NAFLD/NASH pipeline product profiles were evaluated by US gastroenterologists and hepatologists to assess strengths, weaknesses, and physician receptivity EXTON, Pa., June 1, 2022 /PRNewswire/ — Spherix recently surveyed 103 US gastroenterologists and 20 hepatologists, along with conducting eight qualitative interviews (including 2 KOLs and 6 clinical trial participants), to assess the current and future management of […]